What Альфарона Treats: Main Uses and Benefits

Альфарона (Interferon alfa-2b) is primarily focused on managing conditions characterized by heightened physiological stress stemming from persistent viral activity or the uncontrolled proliferation of malignant cells. The medication is relevant for easing symptom burden across several major therapeutic domains, focusing on chronic disease processes.

It is commonly used to manage chronic Hepatitis B and C viral infections, certain cancers like Hairy Cell Leukemia, Malignant Melanoma (as adjuvant therapy), and AIDS-related Kaposi's Sarcoma, as well as localized viral lesions like Condylomata Acuminata (genital or perianal warts).

The core benefit is focused on managing specific disease processes, which helps moderate disease progression and supports general well-being during symptomatic phases. It is often applied in scenarios where additional management of discomfort is required during episodes of heightened symptoms.

---

Quick Fact: Relief for Viral and Malignant Cell Activity

The drug is relevant in clinical settings that involve chronic or high-risk disease patterns and is generally used to help manage symptom clusters that may become intense or disruptive, offering supportive symptom management across oncology and hepatology domains.

Regulatory References

1. NIH MedlinePlus Drug Information

Альфарона (Interferon Alfa-2b) is restricted by specific population criteria documented by health authorities. Absolute contraindications prohibit its use in several patient groups, as listed in official prescribing information. These include patients with known hypersensitivity to the product, a history of severe psychiatric disorders (such as major depression or suicidal ideation), decompensated liver disease, autoimmune hepatitis, or severe, uncontrolled cardiovascular disease (like recent stroke or unstable angina). Use is also prohibited in patients with uncontrolled thyroid disease.

Age-Related and Conditional Use The medicine is generally approved for adults across all labeled indications. For children, use is restricted to chronic Hepatitis B (approved for ages 1 year and older) and chronic Hepatitis C (approved for ages 3 years and older). Safety and efficacy have not been established for non-Hepatitis pediatric cancers. Caution and close monitoring are required for patients with severe kidney disease, pre-existing autoimmune disorders, or diabetic retinopathy.

Reproductive Status Use during pregnancy is generally not recommended (Category C), and women of childbearing potential must use effective contraception. When used in combination with ribavirin, the regimen is absolutely contraindicated in pregnant women.

Interactions with other medicines and products

The official regulatory profile for Interferon Alfa-2b interactions focuses on pharmacokinetic alterations and additive pharmacodynamic effects. The interactions are generally classified as requiring close caution and clinical monitoring as documented by government health authorities.

Documented Pharmacokinetic Interactions

Co-administration with other medicinal products may result in a reduction in the clearance of those agents, a process attributed to the effect of Interferon Alfa-2b on hepatic microsomal enzyme systems. This documented pharmacokinetic interaction can lead to increased plasma concentrations of the co-administered drug. The drug Theophylline is specifically cited in official labeling as an agent whose clearance is reduced, requiring careful assessment of systemic exposure.

Documented Pharmacodynamic Interactions

Interferon Alfa-2b has the potential for additive effects when combined with other substance categories:

• Central Nervous System (CNS) Potentiation: The co-administration of CNS-active medications, such as hypnotics or sedatives, may increase the potential for additive effects on the central nervous system.
• Myelosuppression Potentiation: When used concurrently with other myelosuppressive agents, there is an increased risk of additive suppression of bone marrow function, which necessitates monitoring of blood counts.

Other Substance Interactions and Constraints

While no absolute contraindications are listed based solely on interaction mechanism, official labeling includes cautionary notes. Patients with chronic viral hepatitis are advised against excessive alcohol consumption due to a potential increase in hepatotoxicity risk. No specific timing-based interaction rules (e.g., must be separated by X hours) are explicitly documented in regulatory materials for co-administered drugs.

How Альфарона Works: The Mechanism of Action

Interferon Receptor Activation and Gene Signaling

Альфарона ( Interferon alpha-2b) works as an agonist, binding to the Interferon Alpha/Beta Receptor ( IFNAR) present on host cells . This binding immediately activates the JAK-STAT signaling pathway, which transmits a signal directly to the nucleus. This molecular cascade results in the transcription and synthesis of numerous Interferon-Stimulated Genes ( ISGs).

---

Induction of the Cellular Antiviral State

The proteins produced from the activated ISGs (such as PKR and 2^prime-5^prime OAS) establish a cellular antiviral state. These proteins directly interfere with the ability of infectious agents to copy their genetic material and assemble new particles, resulting in the inhibition of viral replication kinetics at the cellular level.

---

Immune System Modulation and Growth Control

Альфарона modulates the innate immune system, primarily by enhancing the activity of surveillance cells like Natural Killer ( NK) cells. Furthermore, its mechanism includes influencing cell cycle regulation, resulting in the induction of the programmed death ( apoptosis) of proliferating cells. This dual action contributes to the modulation of immune function and the regulation of cellular proliferation.

How Альфарона (Interferon alfa-2b) is Used: Official Administration Guidelines

Альфарона is administered by injection, following highly specific schedules and dose calculations. The method of administration is strictly tied to the condition being managed.

Approved Routes and Dosing Regimens

The medicine is formulated as a powder requiring reconstitution or as a solution for injection. The approved routes include subcutaneous (SC), intramuscular (IM), intralesional (IL), and intravenous (IV).

Indication	Dose	Route	Frequency / Duration Pattern
Malignant Melanoma	20 million IU/m^2 (Induction)	IV infusion	5 times/week for 4 weeks (Induction)
	10 million IU/m^2 (Maintenance)	SC	3 times/week for 48 weeks (Maintenance)
Hairy Cell Leukemia	2 million IU/m^2	IM or SC	3 times/week for up to 6 months
Chronic Hepatitis B	5 to 10 million IU	IM or SC	3 times/week for a period of 16 to 24 weeks

Preparation and Administration Protocol

For intravenous (IV) use (e.g., in the induction phase for Malignant Melanoma), the prescribed dose is added to a 0.9% sodium chloride solution and administered as a controlled 20-minute infusion. Subcutaneous and Intramuscular doses should be injected in different locations (e.g., thighs, abdomen, upper arms), with sites rotated for each dose. For the treatment of localized lesions, the drug is given via intralesional injection on alternate days.

Dosing Adjustments and Special Instructions

Treatment initiation is recommended to occur under the supervision of a physician experienced in the management of the respective condition. Dosing may be calculated based on the patient's body surface area (IU/m^2) for many indications, including pediatric use. Instructions mandate a 50% dose reduction or temporary discontinuation if specific laboratory abnormalities develop, such as severe haematological toxicity.

Research Evidence / Overview of Studies for Альфарона (Interferon alfa-2b)

---

Evidence for Chronic Viral Hepatitis (Hepatitis B and C)

Research has evaluated Interferon alfa-2b as a treatment option for chronic Hepatitis B and C infections. For Hepatitis C, studies typically involved combination therapy, where they monitored outcomes such as Sustained Virologic Response (SVR), meaning the virus remains undetectable six months after therapy is complete. Studies also measured changes in liver enzyme levels. Findings describe patterns observed in the studies that included measurements related to virologic clearance in certain patient groups, particularly when the drug was studied for shorter periods.

For Hepatitis B, studies examined measures like seroconversion (a sign that the body is responding to the virus) and a reduction in the level of virus detected in the blood. The data show patterns related to viral reduction but also indicate that a portion of patients experienced the virus becoming detectable again after treatment ended. The certainty remains low when referencing these historical findings, given the evolution of modern therapeutic standards.

---

Evidence for Cancers: Hairy Cell Leukemia and Malignant Melanoma

For Hairy Cell Leukemia, research was observed in both controlled and uncontrolled clinical settings, focusing on how patients' blood cell counts changed over time, aiming for Complete Response (CR) or Partial Response (PR). These trials contribute to the broader evidence landscape by documenting that patterns observed in the studies included measurements related to blood count changes. However, research describes that the condition was associated with disease relapse following treatment cessation.

For Malignant Melanoma, especially in the high-risk setting following surgery (adjuvant therapy), large Randomized Controlled Trials (RCTs) monitored two main outcomes: Disease-Free Survival (DFS) and Overall Survival (OS). Research so far indicates that certain dosing regimens may be associated with a delayed recurrence of the cancer (extended DFS). However, when researchers synthesize the findings from multiple trials, the data was observed in some studies to be mixed regarding the measured outcome of Overall Survival, meaning the observation of Overall Survival is not fully established or consistently reported across all studies.

---

Summary of Evidence Limitations and Areas of Uncertainty

It is important to understand that the evidence quality varies across studies for the different conditions. For instance, the long-term effects are not fully established when studied for melanoma, and follow-up durations were limited in some of the key initial trials. The overall research evidence highlights what is known — and what is still uncertain, often pointing to the need for more comparative evidence against newer standard treatments, especially in the viral hepatitis domain. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

1. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group
2. Interferon Alfa-2b Injection: MedlinePlus Drug Information

Common questions about Альфарона (FAQ)

Q: How quickly does Альфарона start working?

Альфарона may begin relieving symptoms within 4 hours of the first dose. Clinical studies indicate a significant improvement in a dog's signs may be observed within 24 hours of administration.

The product labeling suggests that many dogs show relief shortly after the initial dose, but individual response times can vary.

---

Q: Can I give my dog a lower dose if the itching stops?

The product information emphasizes following the exact dosage schedule prescribed by a veterinarian. Альфарона should only be used according to the medical direction provided.

Adjusting the dose or stopping treatment without veterinary guidance may lead to a return of the original clinical signs. Any changes to the medication schedule should be discussed with the prescribing veterinarian.

---

Q: What are the long-term side effects of Альфарона?

Альфарона has been studied for long-term use. The most commonly reported side effects include minor gastrointestinal issues, such as vomiting and diarrhea.

The prescribing information notes that increased susceptibility to infection and development of neoplasia (cancer) have been reported in some dogs. Because of this, regular follow-up and monitoring with a veterinarian are essential to assess the ongoing risk and benefit for the individual pet.

How to Store and Dispose of Альфарона?

The storage and disposal of Альфарона ( Interferon alfa-2b) must follow strict regulatory conditions to ensure product stability and safety.

Storage Requirements

• Mandatory Temperature: The medicine must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F). It is critical that the product does not freeze.
• Protection: Keep the product in its original outer carton to protect it from light. The container must be kept tightly closed.
• Stability: If the lyophilized powder is reconstituted, the solution must be used immediately or within 24 hours if refrigerated. Multi-dose vials or pens must be discarded 28 days after first use.
• Child Safety: Store the medicine, needles, and all supplies out of the sight and reach of children.

Disposal Instructions

• Sharps: Used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container.
• Unused Product: Unused or expired Альфарона must be disposed of via an approved waste disposal plant or according to local regulations. Environmental release, particularly into drains or waterways, must be avoided.